Literature DB >> 14997566

Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site.

Hugo Gutiérrez-de-Terán1, Nuria B Centeno, Manuel Pastor, Ferran Sanz.   

Abstract

The present work describes the building of a human A(1) adenosine receptor (hA(1)AR) model, based on the X-ray crystal structure of bovine rhodopsin, and its use as a basis for the investigation of some important structural characteristics of the receptor. One of the issues investigated was the protonation position of two histidine residues known to influence ligand binding, with protonation of His251 (6.52) in epsilon position and His278 (7.43) in delta position showing the best agreement with experimental evidence. The model was also used to study the position and structural role of water molecules present in the helical bundle. Finally, the binding site location and the ligand docking were investigated using an objective strategy. A suitable site for the binding of the ribose moiety of adenosine was first postulated and further confirmed by means of a novel chemometric strategy based on GRIND descriptors. Using this position as an anchor point, the binding of adenosine was studied by docking and molecular dynamics simulations obtaining two putative binding positions in good agreement with experimental data. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997566     DOI: 10.1002/prot.10617

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  2 in total

1.  Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists+.

Authors:  Prosenjit Bhattacharya; J Thomas Leonard; Kunal Roy
Journal:  J Mol Model       Date:  2005-06-01       Impact factor: 1.810

2.  Comparative modelling of protein structure and its impact on microbial cell factories.

Authors:  Nuria B Centeno; Joan Planas-Iglesias; Baldomero Oliva
Journal:  Microb Cell Fact       Date:  2005-06-30       Impact factor: 5.328

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.